• LongBio Pharma will hold an extraordinary general meeting in Shanghai, China on Sept. 10, 2026.
• Shareholders will vote on appointing Xue Kailu as a non-executive director.
• The meeting will also consider his proposed annual director’s fee of RMB 250,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12295196), on August 21, 2026, and is solely responsible for the information contained therein.